Sanofi
About Sanofi
Sanofi is a global biopharmaceutical company focused on research and development-driven medicines and vaccines. It operates across therapeutic areas including immunology, neurology, oncology, and rare diseases, with a commitment to innovative healthcare solutions worldwide. The company emphasizes digital and AI-powered approaches in R&D to advance breakthroughs and improve patient outcomes, pursuing sustainable growth and access to healthcare benefits. Headquartered with global reach, Sanofi engages in external innovation, manufacturing, and patient engagement as part of its strategy to address critical health challenges.
Recent News
EMA’s CHMP Backs Six New Products in January
Innate Pharma to Participate in the Kempen Life Sciences Conference
New Yellow Fever Vaccine Matches Safety and Effectiveness of Current Shot
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Burnout Common but Regrets Are Not in Allergy, Immunology
Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease
FDA Delays Decision on Sanofi's Subcutaneous Sarclisa
Sanofi Extends $180M to California T Cell Engager Startup Kali
World Hemophilia Day 2026: New Treatment Era and Improving Diagnosis
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
The 5 Largest IPOs in Biopharma History
Sanofi MS Drug Rejected in US Gets an Endorsement in Europe
Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
Initiation of the Interchangeable Biosimilar Insulin Glargine-Yfgn Among Older Adults
FDA Approves Sanofi's Tzield to Delay Type 1 Diabetes in Children as Young as One Year
Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In
Ocugen Shares Fall, Despite Positive Eye Disorder Trial
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Sanofi Pulls Teplizumab From FDA’s Makary Review Over Political Interference
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies
EU Approves Dupixent for Children 2‑11 with Chronic Spontaneous Urticaria
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Well-Known Genus, Novel Method: A Post-Amgen Framework for Written Description & Enablement
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Q&A: Nephrologist on ‘Evolving’ Field of Kidney Transplantation
Regeneron Q1 2026 Net Income Falls 10% to $727m
FDA Expands Teplizumab-Mzwv Approval to Young Children With Stage 2 T1D
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
In the Clinic for May 20, 2026
Regulatory Actions for April 24, 2026
Obesity Drugs Unlikely to Cause Combined Oral Contraceptive Failure
HrFlow.ai Secures €6 Million Pre-Series A to Build “Hiring SuperIntelligence” To Tackle Unemployment
WEF Highlights 32 AI Case Studies with Real-World Business Impact
Ocrelizumab Preserves Ambulation, Hand Function in MS
Regeneron Basks in First Gene Therapy Approval as Dupixent, Eylea Carry Robust Q1 Earnings
Proteasomes: A Novel Approach to Target the Immune System
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Sanofi Posts Upbeat Sales as R&D Pressure Builds
Top Biotech Deals in March 2026
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
Recent Deals
Enable Injections Secures $30M Corporate Investment From Sanofi
Alveus Therapeutics Secures $37M Series A Extension Funding
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Sanofi Invests $180M in T-Cell Engager Startup Kali
Electra Therapeutics Raises $183M in Series C Led by Nextech and EQT Life Sciences